LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

Novo Nordisk A-S

Chiusa

SettoreSettore sanitario

56.36 -0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.76

Massimo

57.16

Metriche Chiave

By Trading Economics

Entrata

-2.5B

27B

Vendite

-1.2B

77B

P/E

Media del settore

14.483

35.724

EPS

6.53

Rendimento da dividendi

3.03

Margine di Profitto

34.484

Dipendenti

78,387

EBITDA

-2.5B

44B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+19.68% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.03%

3.09%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

28B

244B

Apertura precedente

56.59

Chiusura precedente

56.36

Notizie sul Sentiment di mercato

By Acuity

95%

5%

359 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Novo Nordisk A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 ago 2025, 13:52 UTC

I principali Market Mover

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 ago 2025, 09:23 UTC

I principali Market Mover

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 ago 2025, 09:23 UTC

I principali Market Mover

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 ago 2025, 06:52 UTC

Utili

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 ago 2025, 06:21 UTC

Utili

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2 set 2025, 09:14 UTC

Azioni calde

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 ago 2025, 08:49 UTC

Utili
Azioni calde

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 ago 2025, 09:23 UTC

Azioni calde

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 ago 2025, 05:32 UTC

Discorsi di Mercato

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 ago 2025, 11:32 UTC

Utili

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 11:03 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 ago 2025, 10:41 UTC

Utili

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 ago 2025, 20:34 UTC

Utili

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 ago 2025, 08:45 UTC

Utili

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 ago 2025, 07:19 UTC

Discorsi di Mercato
Utili

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 ago 2025, 05:50 UTC

Utili

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 ago 2025, 05:48 UTC

Utili

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 ago 2025, 05:46 UTC

Utili

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 ago 2025, 05:38 UTC

Utili

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 ago 2025, 05:37 UTC

Utili

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 ago 2025, 05:36 UTC

Utili

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 ago 2025, 05:35 UTC

Utili

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 ago 2025, 05:34 UTC

Utili

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Net Pft DKK26.5B

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Oper Pft DKK33.45B

6 ago 2025, 05:31 UTC

Utili

Novo Nordisk 2Q Sales DKK76.86B

5 ago 2025, 21:58 UTC

Utili

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 17:26 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 ago 2025, 15:15 UTC

Utili

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5 ago 2025, 10:07 UTC

Discorsi di Mercato

Novo Nordisk's Facing Challenging Times -- Market Talk

Confronto tra pari

Modifica del prezzo

Novo Nordisk A-S Previsione

Obiettivo di Prezzo

By TipRanks

19.68% in crescita

Previsioni per 12 mesi

Media 67.57 USD  19.68%

Alto 90 USD

Basso 50 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

2

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

62.63 / 69.23Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

359 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.